NCT01061580

BMAC Enhanced Coronary Artery Bypass Grafting (CABG)

Dose Response Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting (CABG) Surgery

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Harvest Technologies · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Injection of concentrated bone marrow cells into the myocardium during CABG procedure.

Detailed description

Injection of autologous concentrated bone marrow cells into the myocardium during CABG procedure.

Conditions

• Congestive Heart Failure

Interventions

Type	Name	Description
DEVICE	Harvest SmartPReP2 BMAC System	Injection of 10, 15, or 20 cc of BMAC

Timeline

• Start date: 2010-05-01
• Primary completion: 2012-12-01
• Completion: 2013-12-01
• First posted: 2010-02-03
• Last updated: 2014-06-26

Locations

1 site across 1 country: India